CONSHOHOCKEN, PA--(Marketwire - March 11, 2011) - NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that Jane Hollingsworth, chief executive officer, will present a company overview at the Roth 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011 at 7:30 p.m. EDT. The conference is being held at The Ritz Carlton in Laguna Niguel, CA.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the NuPathe website, www.nupathe.com. Please log on through NuPathe’s website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company’s website for 90 days following the call.
About NuPathe
NuPathe Inc. (www.nupathe.com) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe’s most advanced product candidate, Zelrix, is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: NP201 for the continuous symptomatic treatment of Parkinson’s disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder.
Contact Information:
John Woolford
(443) 213-0506
Email Contact
Keith A. Goldan
Vice President, Chief Financial Officer
NuPathe Inc.
(484) 567-0130
Media Contacts:
Ron Schmid
NuPathe Inc.
(610) 659-3985
